SII to resume Covid vaccine trials once DCGI gives nod (Ld)

SII to resume Covid vaccine trials once DCGI gives nod (Ld)

An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step. The company said it will continue to work with health authorities "across the world" and "be guided" as to when other clinical trials can resume.

Oxford University, where the vaccine was developed, said in a separate statement that the nature of the illness can not be revealed "for reasons of participant confidentiality". The news was met with a range of questions from skeptics from some western countries and scientists, mainly because the vaccine had received approval before full clinical trials have been completed.

Rakova added that the volunteers will receive a second shot of the same vaccine within 21 days of the first.

Seven out of a total of 135 vaccines have managed to reach the third stage of clinical trials, she said.

According to the statement, the trials have been carried out in three other countries: Bahrain, the UAE and Jordan.

Malta and other European Union states will be acquiring doses of that vaccine and news of the postponed trials sparked fears that procurement will be delayed.

Linguori concludes: "AstraZeneca, by voluntarily suspending the new tests, has demonstrated that safety comes first".

Currently, global trials of this vaccine were halted on 8 September, after a patient who was administered this vaccine had reportedly fallen ill.

Russian Federation began first deliveries of the Sputnik V vaccine for the general public this week.

The vaccine uses mRNA - the genetic messenger the body uses to make the DNA code into proteins - packaged inside a fatty capsule, called a lipid nanoparticle, that allows it to get into cells.

In fact, Ad5-nCoV became China's first Covid-19 vaccine to be granted invention patent by the authorities.

The next step in studying any vaccine is to confirm that it can effectively protect against COVID-19 infection.

The news that the vaccine trials have restarted will be welcomed across the world since global vaccination sites in Brazil, South Africa and the U.S. had to be put on hold last week. The vaccine's phase III trials are now underway and it is being administered to over 40,000 people.

Serum Institute of India is all set to restart clinical trials of AstraZeneca's COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI), the Pune-based vaccine manufacturer said on Saturday. The phase I and Phase II trial of this vaccine have shown good immune response in older candidates of the age 60 years and above.

With the testing now back on, a vaccine could possibly be ready by the end of the year.

Also, phase 3 trials by Sinopharm's CNBG have started in Morocco, Peru and Argentina.

Related Articles